LENZ Therapeutics launches VIZZ eye drop for presbyopia in U.S.; samples shipped

LENZ Therapeutics, Inc.

VIZZ (aceclidine 1.44%) first FDA-approved aceclidine-based eye drop for presbyopia, now commercially available.
Professional sample distribution to optometrists and ophthalmologists initiated nationwide.
Commercial product shipments to consumers via ePharmacy starting October; broad availability by mid-Q4 2025.
93% of Phase 3 CLARITY trial participants achieved 20/40 near vision within 30 minutes, lasting up to 10 hours.
Addresses ~128 million U.S. adults with blurry near vision; CEO calls it a 'Category of One'.

item 7.01item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.